Diabetic peripheral angiopathy
diseaseOn this page
Also known as diabetic angiopathydiabetic vascular disorder
Summary
Diabetic peripheral angiopathy (MONDO:0000960) is a disease and 16 clinical trials. Top therapeutic interventions include valsartan and calcium dobesilate. A subtype of peripheral vascular disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 16
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | diabetic peripheral angiopathy |
| Mondo ID | MONDO:0000960 |
| EFO | EFO:1000896 |
| MeSH | D003925 |
| DOID | DOID:10182, DOID:11713 |
| NCIT | C35610 |
| SNOMED CT | 127014009 |
| UMLS | C0011871 |
| MedGen | 507633 |
| Is cancer (heuristic) | no |
Also known as: diabetic angiopathy · diabetic vascular disorder
Disease family
This is a subtype of peripheral vascular disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › peripheral vascular disease › diabetic peripheral angiopathy
Related subtypes (10): telangiectasis, priapism, intermittent vascular claudication, peripheral arterial disease, mesenteric vascular occlusion, Raynaud disease, thromboangiitis obliterans, erythromelalgia, May-Thurner syndrome, livedo reticularis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bemiparin.
Clinical trials & evidence
Clinical trials
Clinical trials: 16.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE4 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05095922 | PHASE4 | COMPLETED | Effect of HMP on Diabetic Microangiopaemia in T2DM |
| NCT05906199 | PHASE4 | COMPLETED | A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy. |
| NCT00399425 | PHASE2/PHASE3 | TERMINATED | Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients |
| NCT01746563 | PHASE1/PHASE2 | COMPLETED | Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy |
| NCT02864654 | PHASE1/PHASE2 | UNKNOWN | Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia |
| NCT03594344 | Not specified | RECRUITING | Additional Hyperbaric Oxygen After Lower Extremity Amputation |
| NCT05282680 | Not specified | ACTIVE_NOT_RECRUITING | The Hong Kong Diabetes Biobank |
| NCT06485362 | Not specified | NOT_YET_RECRUITING | Use of Thermography for the Prevention and Diagnosis of Diabetic Foot |
| NCT06674980 | Not specified | RECRUITING | Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs |
| NCT00134277 | Not specified | COMPLETED | Trial Comparing Different Medical Devices for Infragenual Dilatation |
| NCT02001532 | Not specified | COMPLETED | Arterial Stiffness and Complication Risk in Type 2 Diabetes |
| NCT02435329 | Not specified | COMPLETED | Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study |
| NCT02882945 | Not specified | COMPLETED | Gene Polymorphism Associated With Macroangiopathy in Type 2 Diabetes Patients |
| NCT03603990 | Not specified | WITHDRAWN | Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema |
| NCT04567563 | Not specified | UNKNOWN | Remote Ischemic Conditioning and Diabetic Foot Ulcers |
| NCT05068895 | Not specified | UNKNOWN | Assessment of Metabolic Profiles of Lower Extremity Arterial Disease in Patiens Withe Type 2 Diabetes |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| VALSARTAN | 4 | 1 |
| CALCIUM DOBESILATE | 3 | 1 |
Related Atlas pages
- Drugs: Valsartan